I agree that NP needs to deliver based on a deadli

I agree that NP needs to deliver based on a deadline.
We had three or more misses on the timing on the HIV BLA.
The last one - Oct 15 came and went even though it was promised after a supposedly thorough review.
I don’t buy the argument that the BLA is not important anymore.
When you set a date a few months out after supposedly thorough research you need to hit it or be close not be 4-6 months off - remember this is at least the third miss on this when each time we were told that CYDY understood what the FDA was looking for and had in their control what was needed to answer the FDA questions.
You really can’t have it both ways- building expectations and never hitting ones that produce significant revenue.
The share price shows how the market feels about the company performance.
NP was recently given over 4 million ( I think 4.7 million) options at 1.39. If there are instead sold on the open market, it would have generated more that 6 million in cash- the effect on dilution is the same.
I really like NPs transparency but am really frustrated at the lack of delivery on the promises.
IMO